Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: A systematic review of prospective studies

Haemophilia

Volumn 18, Issue 3, 2012, Pages

  Coppola, A ^a   Franchini, M ^b   Makris, M ^c   Santagostino, E ^d   Di Minno, G ^a   Mannucci, Pier M ^e  

^a FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^b CARLO POMA HOSPITAL   (Italy)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d A Bianchi Bonomi Hemophilia and Thrombosis Center   (Italy)

^e FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Adverse events; Factor concentrates; Haemophilia; Safety; Thrombosis; Von Willebrand disease

Indexed keywords

CARDIOVASCULAR RISK; HEMOPHILIA; HUMAN; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SUPERFICIAL THROMBOPHLEBITIS; SYSTEMATIC REVIEW; THROMBOSIS; VASCULAR ACCESS; VENOUS THROMBOEMBOLISM; VON WILLEBRAND DISEASE;

BLOOD COAGULATION FACTORS; HEMOPHILIA A; HEMOPHILIA B; HUMANS; INCIDENCE; PROSPECTIVE STUDIES; THROMBOSIS; VON WILLEBRAND DISEASES;

EID: 84860333511     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2012.02758.x     Document Type: Review

References (112)

1. Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 2008; 14: 671-84.
2. Santagostino E, Mannucci PM; for the Italian Association of Haemophilia Centres (AICE). Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy. Haemophilia 2000; 6: 1-10.
3. Mannucci PM, Tuddenham EG. The hemophilias - from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-9.
4. Mannucci PM, Franchini M, Castaman G, Federici AB; on behalf of AICE (Italian Association of Haemophilia Centres). Evidence-based recommendations on the treatment of von Willebrand disease in Italy. Blood Transfus 2009; 7: 117-26.
5. Brooker M. Registry of clotting Factor Concentrates, Eight Edition, 2008. Facts and Figures monograph n. 6. World Federation of Haemophilia. Available at Accessed November 6, 2011.
6. Pipe S. Hemophilia: new protein therapeutics. Hematology Am Soc Hematol Educ Program 2010; 2010: 203-9.
7. Mannucci PM. Back to the future: a recent history of hemophilia treatment. Haemophilia 2008; 14(Suppl. 3): 10-8.
8. Tagliaferri A, Rivolta GF, Iorio A et al. Mortality and cause of death in Italian persons with haemophilia, 1990-2007. Haemophilia 2010; 16: 437-46.
9. Turecek PL, Schrenk G, Rottensteiner H et al. Structure and function of a recombinant von Willebrand factor drug candidate. Semin Thromb Hemost 2010; 36: 510-21.
10. Franchini M, Mannucci PM. Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice. Br J Clin Pharmacol 2011; 72: 553-62.
11. Scharrer I. The need for highly purified products to treat haemophilia B. Acta Haematol 1995; 94(Suppl 1): 2-7.
12. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004; 2: 1700-8.
13. Girolami A, Ruzzon E, Fabris F, Varvarikis C, Sartori R, Girolami B. Myocardial infarction and other arterial occlusions in hemophilia A patients. Acta Haematol 2006; 116: 120-5.
14. Girolami A, Randi ML, Ruzzon E, Zanon E, Girolami B. Myocardial infarction, other arterial thrombosis and invasive coronary procedures in hemophilia B: a critical evaluation of reported cases. J Thromb Thrombolysis 2005; 20: 43-6.
15. Girolami A, Scandellari R, Zanon E, Sartori R, Girolami B. Non-catheter associated venous thrombosis in haemophilia A and B. A critical review of all reported cases. J Thromb Thrombolys 2006; 21: 279-84.
16. Makris M, Colvin B, Gupta V, Shields ML, Smith MP. Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease. Thromb Haemost 2002; 88: 387-8.
17. Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost 2002; 88: 378-9.
18. Koster T, Blann AD, Brief E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-5.
19. European Commission. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Available at 2004. Accessed November 6, 2011.
20. Lusher JM, Salzman PM, and the Monoclate Study Group. Viral safety and inhibitor development associated with factor VIIIC ultra-purified from plasma in hemophiliacs previously unexposed to factor VIIIC concentrates. Semin Hematol 1990; 27(Suppl 2): 1-7.
21. Schwartz RS, Abildgaard CF, Aledort LM et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group. N Engl I Med 1990; 323: 1800-5.
22. Bray GL, Gomperts ED, Courter SG. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients. Blood 1994; 83: 2428-35.
23. Aygoren-Pursun E, Sharrer I; The German Kogenate Study Group. A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. Thromb Haemost 1997; 78: 1352-6.
24. White GC II, Courter S, Bray GL, Lee M, Gomperts ED. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. Thromb Haemost 1997; 77: 660-7.
25. Seremetis S, Lusher JM, Abildgaard CF, Kasper CK, Allred R, Hurst D. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. Haemophilia 1999; 5: 9-16.
26. Abshire TC, Brackmann HH, Scharrer I et al. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy - International Kogenate-FS Study Group. Thromb Haemost 2000; 83: 811-6.
27. Scharrer I, Brackmann HH, Sultan I et al. Efficacy of sucrose-formulated recombinant factor VIII used for 22 surgical procedures in patients with severe hemophilia A. Haemophilia 2000; 6: 614-8.
28. Powell JS, Bush M, Harrison J et al. Safety and efficacy of solvent/detergent-treated antihaemophilic factor with an added 80°C terminal dry heat treatment in patients with haemophilia A. Haemophilia 2000; 6: 140-9.
29. Yoshioka A, Shima M, Fukutake K, Takamatsu J, Shirahata A; Kogenate FS Study Group. Safety and efficacy of a new recombinant FVIII formulated with sucrose (rFVIII-FS) in patients with haemophilia A: a long-term, multicentre clinical study in Japan. Haemophilia 2001; 7: 242-9.
30. Rothschild C, Scharrer I, Brackmann HH et al. European data of a clinical trial with a sucrose formulated recombinant factor VIII in previously treated haemophilia A patients. Haemophilia 2002; 8(Suppl. 2): 10-4.
31. Lusher JM, Lee CA, Kessler CM, Bedrosian CL, ReFacto Phase 3 Study Group. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 2003; 9: 38-49.
32. Yoshioka A, Fukutake K, Takamatsu J, Shirahata A, Kogenate Post-Marketing Surveillance Study Group. Clinical evaluation of a recombinant factor VIII preparation (Kogenate) in previously untreated patients with hemophilia A. Int J Hematol 2003; 78: 467-74.
33. Vossebeld PJM, Tissing MH, van den Berg HM et al. In vivo recovery and safety of human factor VIII product AAFACT in patients with haemophilia A. Haemophilia 2003; 9: 157-63.
34. Lusher J, Abildgaard C, Arkin S et al. Recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation. J Thromb Haemost 2004; 2: 574-83.
35. Tarantino MD, Collins PW, Hay CR et al. ; RAHF-PFM Clinical Study Group Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia 2004; 10: 428-37.
36. Wolf DM, Rokicka-Milewska R, Lopaciuk S et al. Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia A. Haemophilia 2004; 10: 438-48.
37. Smith MP, Giangrande P, Pollman H et al. A postmarketing surveillance study of the safety and efficacy of ReFacto (St Louis-derived active substance) in patients with haemophilia A. Haemophilia 2005; 11: 444-51.
38. Kreuz W, Gill JC, Rothschild C et al. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation. Thromb Haemost 2005; 3: 457-67.
39. Bidlingmaier C, Deml M-M, Kurnik K. Continuous infusion of factor concentrates in children with haemophilia A in comparison with bolus injections. Haemophilia 2006; 12: 212-7.
40. Pollmann H, Externest D, Ganser A et al. Efficacy, safety and tolerability of recombinant factor VIII (REFACTO) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria. Haemophilia 2007; 13: 131-43.
41. Shi J, Zhao Y, Wu J, Sun J, Wang L, Yang R. Safety and efficacy of a sucrose-formulated recombinant factor VIII product for the treatment of previously treated patients with haemophilia A in China. Haemophilia 2007; 13: 351-6.
42. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
43. Nemes L, Lissitchkov T, Klukowska A et al. Evaluation of pharmacokinetics, efficacy and safety of immunate solvent detergent in previously treated patients with severe hemophilia A. Haemophilia 2007; 13: 9-11.
44. Mauser-Bunschoten EP, Posthouwer D, Fischer K, van den Berg HM. Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10years of follow-up. Haemophilia 2007; 13: 697-700.
45. Blanchette VS, Shapiro AD, Liesner RJ et al. ; rAHF-PFM Clinical Study Group Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost 2008; 6: 1319-26.
46. Delumeau JC, Ikegawa C, Yokoyama C, Haupt V. An observational study of sucrose-formulated recombinant factor VIII for Japanese patients with haemophilia A. Thromb Haemost 2008; 100: 32-7.
47. Musso R, Santagostino E, Faradji A et al. ; KOGENATE Bayer European PMS Study Group Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting. Thromb Haemost 2008; 99: 52-8.
48. Negrier C, Shapiro A, Berntorp E et al. Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of ADVATE in previously treated patients. Thromb Haemost 2008; 100: 217-23.
49. Petrini P, Rylander C. Clinical safety surveillance study of the safety and efficacy of long-term home treatment with ReFacto utilizing a computer-aided diary: a Nordic multicentre study. Haemophilia 2009; 100: 32-7.
50. Young JH, Liu HC, Hsueh EJ et al. Efficacy and safety evaluation of sucrose-formulated recombinant factor VIII for Taiwanese patients with haemophilia A. Haemophilia 2009; 15: 968-70.
51. Recht M, Nemes L, Matysiak M et al. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII. Haemophilia 2009; 15: 869-80.
52. Den Uijl I, Mauser-Bunschoten EP, Rosendaal G, Schutgens R, Fischer K. Efficacy assessment of a new clotting factor concentrate in haemophilia A patients, including prophylactic treatment. Haemophilia 2009; 15: 1215-8.
53. Martinowitz U, Luboshitz J, Bashari D et al. Stability, efficacy and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia. Haemophilia 2009; 15: 676-85.
54. Oldenburg J, Goudemand J, Valentino L et al. Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice. Haemophilia 2010; 16: 866-77.
55. Collins P, Faradji A, Morfini M, Enriquez MM, Schwartz L. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. J Thromb Haemost 2010; 8: 83-9.
56. Vidovic N, Musso R, Klamroth R, Enriquez MM, Achilles K. Postmarketing surveillance study of KOGENATE Bayer with Bio-Set in patients with haemophilia A: evaluation of patients' satisfaction after switch to the new reconstitution system. Haemophilia 2010; 16: 66-71.
57. Wyndiga J, Rusen L, Gruppo R et al. BBDrFVIII (Morotocog alfa [AF-CC]) for surgical haemostasis in patients with haemophilia A: results of a pivotal study. Haemophilia 2010; 16: 731-9.
58. Dmoszynska A, Kuliczkowski K, Hellmann A et al. Clinical assessment of Optivate, a high-purity concentrate of factor VIII with von Willebrand factor, in the management of patients with haemophilia A. Haemophilia 2011; 17: 456-62.
59. Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM and the ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with haemophilia A (the ESPRIT study). J Thromb Haemost 2011; 9: 700-10.
60. Matysiak M, Bobrowska H, Balwierz W et al. Clinical experience with Optivate, high-purity factor VIII (FVIII) product with von Willebrand factor (VWF) in young children with haemophilia A. Haemophilia 2011; 17: 737-42.
61. Klukowska A, Komrska V, Jansen M, Laguna P. Incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study. Haemophilia 2011; 17: 399-406.
62. Klukowska A, Windyga J, Batorova A. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate, in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients. Thromb Res 2011; 127: 247-53.
63. Zhang L, Zhao Y, Sun J, Wang X, Yu M, Yang R. Clinical observation on safety and efficacy of a plasma- and albumin-free recombinant factor VIII for no-demand treatment of Chinese patients with haemophilia A. Haemophilia 2011; 17: 191-5.
64. Hay CRM, Hellmann A, Dmoszynska A et al. Experience with Optivate, a new high purity concentrate of factor VIII with von Willebrand factor, in patients undergoing surgery. Haemophilia 2011; 17: 428-32.
65. Goldsmith JC, Kasper CK, Blatt PM et al. Coagulation factor IX: successful surgical experience with a purified factor IX concentrate. Am J Hematol 1992; 40: 210-5. Acta Haematol 1995; 94(Suppl 1): 53-8.
66. White GC II. Safety and recovery of Mononine in multiple-dose, high-dose regimens. 1995.
67. Shapiro AD, Ragni MV, Lusher JM et al. Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with hemophilia B. Thromb Haemost 1996; 75: 30-5.
68. Roth DA, Kessler CM, Pasi KJ et al. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001; 98: 3600-6.
69. Ragni MV, Pasi KJ, White GC et al. Use of recombinant factor IX in subjects with haemophilia B undergoing surgery. Haemophilia 2002; 8: 91-7.
70. Poon MC, Lillicrap D, Hensman C, Card R, Scully MF. Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study. Thromb Haemost 2002; 87: 431-5.
71. Hoots WK, Leissinger C, Stabler S et al. Continuous intravenous infusion of a plasma-derived factor IX concentrate (Mononine) in haemophilia B. Haemophilia 2003; 9: 164-72.
72. Shapiro AD, Di Paola J, Cohen A et al. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood 2005; 105: 518-25.
73. Ruiz-Saez A, Hing A, Arguello A et al. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate. Haemophilia 2005; 11: 583-8.
74. Lambert T, Recht M, Valentino LA et al. Reformulated BeneFIX: efficacy and safety in previously treated patients with moderately severe to severe hemophilia B. Haemophilia 2007; 13: 233-43.
75. Lissitchkow T, Matysiak M, Zavilska K et al. An open clinical study assessing the efficacy and safety of Factor IX Grifols®, a high-purity factor IX concentrate, in patients with severe haemophilia B. Haemophilia 2007; 16: 240-6.
76. Monahan PE, Liesner R, Sullivan ST, Ramirez ME, Kelly P, Roth DA. Safety and efficacy of investigator-prescribed BenefIX prophylaxis in children less than 6years of age with severe hemophilia B. Haemophilia 2010; 16: 460-8.
77. Serban M, Skotnicki AB, Colovic M et al. Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine in previously treated patients with severe hemophilia B. Haemophilia 2012; 18: 175-81.
78. Lissitchkov T, Matysiak M, Zavilska K et al. A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine, a high-purity factor IX concentrate, in patients with severe haemophilia B. Haemophilia 2011; 17: 590-6.
79. Mauser-Bunschoten EP, Kleine Budde I, Lopaciuk S et al. An ultrapure plasma-derived monoclonal antibody-purified factor IX concentrate (Nonafact®), results of phase III and phase IV clinical studies. Haemophilia 2011; 17: 439-45.
80. Lubetsky U, Martinowitz U, Luboshitz J et al. Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experience. Haemophilia 2002; 8: 622-8.
81. Mannucci PM, Chediak J, Hanna W et al. Treatment of von Wilebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood 2002; 99: 450-6.
82. Auerswald G, Eberspacher B, Engl W et al. Successful treatment of patients with von Willebrand disease using a high-purity double-virus inactivated factor VIII/von Willebrand factor concentrate (Immunate). Semin Thromb Hemost 2002; 28: 203-13.
83. Thompson AR, Gill GC, Ewenstein BM, Mueller-Veltens G, Schwartz BA, for the Humate-P Study Group. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P). Haemophilia 2004; 10: 42-51.
84. Ver Elst KMM, van Vliet HDM, Kappers-Klunne MC, Leebeek FWG. In vitro studies, pharmacokinetic studies and clincal use of a high purity double virus inactivated FVIII/VWF concentrate (Immunate) in the treatment of von Willebrand disease. Thromb Haemost 2004; 92: 67-74.
85. Bello IF, Yuste VJ, Molina MQ, Navarro FH. Fanhdi, efficacy and safety in von Willebrand's disease: prospective International study results. Haemophilia 2007; 13(Suppl. 5): 25-32.
86. Lethagen S, Kyrle PA, Castaman G, Haertel S, Mannucci PM, for the Haemate P Surgical Study Group. Von Willebrand factor/factor VIII concentrate (HAEMATE P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. J Thromb Haemost 2007; 5: 1420-30.
87. Borel-Derlon A, Federici AB, Roussel-Robert V et al. Treatment of severe von Willebrand disaese with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost 2007; 5: 1115-24.
88. Berntorp E, Windyga J and The European Wilate Study Group. Treatment and prevention of acute bleedings in von Willebrand disease - efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate. Haemophilia 2009; 15: 122-30.
89. Dunkley S, Baker RI, Pidcock M et al. Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand's disease: a prospective multi-centre study. Haemophilia 2010; 16: 615-24.
90. Windyga J, von Depka Prondzinski M, on behalf of the European Wilate Study Group. Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery. Thromb Haemost 2011; 105: 1072-9.
91. Medeiros D, Miller KL, Rollins NK, Buchnan GR. Contrast venography in young haemophiliacs with implantable central venous access devices. Haemophilia 1998; 4: 10-5.
92. Journeycake JM, Quinn CT, Miller KL, Zajac JL, Buchnan GR. Catheter-related deep venous thrombosis in children with hemophilia. Blood 2001; 98: 1727-31.
93. Tarantino MD, Lail A, Donfield SM et al. Surveillance of infectious complications associated with central venous access devices in children with haemophilia. Haemophilia 2003; 9: 588-92.
94. Berntorp E, Piitulainen E, Lethagen S, Mattson E, Tengborn L, Mätzsch T. Experience with a new percutaneous port system, Percuseal®, for intravenous injection in patients with haemophilia, von Willebrand disease and severe alpha1-amtitrypsin deficiency. Haemophilia 2003; 9: 173-8.
95. Price VE, Carcao M, Connolly B et al. A prospective, longitudinal study of central venous catheter-related deep venous thrombosis in boys with hemophilia. J Thromb Haemost 2004; 2: 737-42.
96. Mancuso ME, Mannucci PM, Sartori A, Agliardi A, Santagostino E. Feasibility of prophylaxis and immune tolerance induction in haemophilic children using fully implantable central venous catheters. Br J Haematol 2008; 141: 689-95.
97. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35.
98. Abshire T, Kenet G. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or factor IX with inhibitors. Haemophilia 2008; 14: 898-902.
99. Aledort LM. Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues. Haemophilia 2008; 14: 39-43.
100. Coppola A, Tagliaferri A, Franchini M. The management of cardiovascular disease in patients with haemophilia. Semin Thromb Haemost 2010; 36: 91-102.
101. Franchini M, Coppola A. Atherothrombosis in von Willebrand disease: an analysis of the literature and implications for clinical management. Semin Thromb Haemost 2012;38: 186-99.
102. Ritchie B, Woodman RC, Poon M-C. Deep venous thrombosis in hemophilia A. Am J Med 1992; 93: 699-700.
103. Stewart AJ, Manson LM, Dennis R, Allan PL, Ludlam CA. Thrombosis in a duplicated superficial vein in a patient with haemophilia A. Haemophilia 2000; 6: 47-9.
104. Franchini M, Targher G, Montagnana M, Lippi G. Antithrombotic prophylaxis in patients with von Willebrand disease undergoing major surgery: when it is necessary? J Thromb Thrombolys 2009; 28: 215-9.
105. Ljiung R. The risk associated with indwelling catheters in children with haemophilia. Br J Haematol 2007; 138: 580-6.
106. Makris M, Calizzani G, Fischer K et al. EUHASS: the European Haemophilia Safety Surveillance System. Thromb Res 2011; 127(Suppl 2): S22-5.
107. Mauser-Bunschoten EP, van de Putte DEF, Schutgens REG. Co-morbidity in the ageing haemophilia patient: the down side of increased life expectancy. Haemophilia 2009; 15: 853-63.
108. Franchini M, Mannucci PM. Co-morbidities and quality of life in elderly persons with haemophilia. Br J Haematol 2010; 148: 522-33.
109. Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients. Semin Hematol 2001; 38(Suppl. 4): 44-51.
110. Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients. Semin Hematol 2001; 38(Suppl. 4): 52-9.
111. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 1993; 328: 453-9.
112. Santagostino E, Gringeri A, Muça Perja M, Mannucci PM. A prospective clinical trial of implantable central venous access in children with haemophilia. Br J Haematol 1998; 102: 1124-8.